Investigators have identified five cases of so-called iatrogenic Alzheimer’s disease (AD), that is, AD that was acquired as a result of undergoing medical procedures. A team led by University College London scientists reported their findings online in Nature Medicine on Jan. 29, 2024. Read More
Phosphodiesterase-4 (PDE4) is an intracellular pro-inflammatory enzyme that is considered a therapeutic target in inflammatory disorders such as psoriasis, asthma or ulcerative colitis (UC), among others. Researchers from Palisade Bio Inc. have reported preclinical data on PALI-2108, a PDE4 inhibitor prodrug, in models of UC. Read More
DP Technology Ltd. has nominated DPT-0218, a novel small molecule targeting Kv1.3, as a preclinical candidate for the treatment of various autoimmune diseases, including inflammatory bowel disease and atopic dermatitis. Read More
Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to be used for the treatment of invasive mucormycosis. Read More
Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. Read More
Kupffer cells are macrophages located in the liver that play a key role in liver pathology, concretely in metabolic dysfunction-associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease or NAFLD), but the mechanisms behind this are poorly understood. Read More
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Shanghai Xianhui Pharmaceutical Co. Ltd. have detailed the discovery and preclinical characterization of novel photosensitizers as candidates for photodynamic therapy (PDT) and photodiagnosis in cancer. Read More
Transcode Therapeutics Inc. has entered into a co-research agreement with Debiopharm SA that will bring together Transcode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer. Read More
Sanofi SA has synthesized cyclic peptides acting as IL-23 receptor (IL-23R) antagonists reported to be useful for the treatment of psoriasis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and hidradenitis suppurativa. Read More
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker. Read More
Ascidian Therapeutics Inc. has received FDA clearance of its IND application for ACDN-01, an RNA exon editor targeting the genetic cause of Stargardt disease. Read More
Ractigen Therapeutics Co. Ltd. has entered into a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University, to advance the development of small activating RNA (saRNA)-based treatments for a spectrum of intractable neurodevelopmental disorders. Read More
Although esketamine, the S-isomer of ketamine, has been approved for treatment-resistant depression, limitations such as dissociative and sedative effects or poor oral bioavailability restrict its use to parenteral dosing and supervised administration. Read More
Bioversys AG has divulged compounds with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors. Read More
Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis. Read More
